Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anterix (ATEX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Anterix (ATEX) over the last 13 years, with Q4 2025 value amounting to $29.5 million.

  • Anterix's Cash & Equivalents rose 255.93% to $29.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.5 million, marking a year-over-year increase of 255.93%. This contributed to the annual value of $47.4 million for FY2025, which is 2179.67% down from last year.
  • According to the latest figures from Q4 2025, Anterix's Cash & Equivalents is $29.5 million, which was up 255.93% from $39.1 million recorded in Q3 2025.
  • Anterix's 5-year Cash & Equivalents high stood at $127.8 million for Q4 2021, and its period low was $28.8 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $64.9 million, with a median of $54.6 million in 2022.
  • As far as peak fluctuations go, Anterix's Cash & Equivalents plummeted by 6641.88% in 2023, and later skyrocketed by 7812.49% in 2024.
  • Over the past 5 years, Anterix's Cash & Equivalents (Quarter) stood at $127.8 million in 2021, then plummeted by 54.99% to $57.5 million in 2022, then grew by 7.86% to $62.0 million in 2023, then crashed by 53.58% to $28.8 million in 2024, then increased by 2.56% to $29.5 million in 2025.
  • Its last three reported values are $29.5 million in Q4 2025, $39.1 million for Q3 2025, and $41.4 million during Q2 2025.